Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -.--% | -.--% |
05-13 | Earnings Flash (CARA) CARA THERAPEUTICS Posts Q1 Revenue $2.1M, vs. Street Est of $1.7M | MT |
05-13 | Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 5.91M 5.27M 8.09M | Sales 2025 * | 4.73M 4.22M 6.48M | Capitalization | 38.01M 33.87M 52.02M |
---|---|---|---|---|---|
Net income 2024 * | -68M -60.6M -93.08M | Net income 2025 * | -64M -57.03M -87.6M | EV / Sales 2024 * | 10.1 x |
Net Debt 2024 * | 21.5M 19.16M 29.43M | Net Debt 2025 * | 78.9M 70.31M 108M | EV / Sales 2025 * | 24.7 x |
P/E ratio 2024 * |
-0.6
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.58% |
Latest transcript on Cara Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.99% | 91.72B | |
0.00% | 39.44B | |
-8.52% | 34.47B | |
+65.59% | 26.7B | |
-17.37% | 15.13B | |
-5.99% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- CARA Stock
- 69C Stock